Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.
Catalyst announces sub-licensee pharma launches FIRDAPSE in Japan
Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Japan, DyDo Pharma has launched FIRDAPSE Tablets 10 mg in Japan for the ...
Yahoo Finance5d
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
Daly, Catalyst’s President and Chief Executive Officer. “The launch of FIRDAPSE in Japan marks another advancement in our efforts to expand the geographic footprint of our portfolio products ...
Nasdaq5d
Catalyst Pharmaceuticals Sub-Licensee DyDo Pharma Launches FIRDAPSE® in Japan for Lambert-Eaton Myasthenic Syndrome
Catalyst Pharmaceuticals, Inc. announced that its sub-licensee, DyDo Pharma, has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan, aimed at improving muscle weakness in patients with ...
Nasdaq5d
Catalyst's FIRDAPSE Approved For Use In Japan, Offering New Hope For LEMS Patients
(RTTNews) - Catalyst Pharmaceuticals, Inc. (CPRX), a commercial-stage biopharmaceutical company, Tuesday announced that its sub-licensee, DyDo Pharma, has launched FIRDAPSE or amifampridine ...
Finanznachrichten5d
Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE in Japan
Daly, Catalyst's President and Chief Executive Officer. "The launch of FIRDAPSE in Japan marks another advancement in our efforts to expand the geographic footprint of our portfolio products and ...